Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Wolfgang Wick" Clear advanced filters

  • Tackling intertumoural and intratumoural heterogeneity is one of the most important challenges in the study and treatment of glioblastoma. A new anatomical transcriptional atlas of human glioblastoma associates established anatomical features with distinct molecular subclasses and provides open access to these well-annotated data for drug target validation and data-mining projects.

    • Wolfgang Wick
    • Tobias Kessler
    News & Views
    Nature Reviews Neurology
    Volume: 14, P: 453-454

  • In 2013, two discoveries—that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma—have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma.

    • Michael Weller
    • Wolfgang Wick
    News & Views
    Nature Reviews Neurology
    Volume: 10, P: 68-70

  • In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.

    • Norbert Hilf
    • Sabrina Kuttruff-Coqui
    • Wolfgang Wick
    Research
    Nature
    Volume: 565, P: 240-245

  • The DNA repair proteinO6-methylguanine-DNA methyltransferase (MGMT) might interfere with alkylating agent chemotherapy in patients with glioma or glioblastoma. In this Review, Wick and colleagues discuss how epigenetic silencing of the MGMT gene via promotor methylation is associated with improved response to chemotherapy, and with improved survival, in patients with glioblastoma and other gliomas. The authors also highlight the usefulness of MGMTpromotor methylation as a biomarker for both clinical practice and the design of treatment trials.

    • Wolfgang Wick
    • Michael Weller
    • Guido Reifenberger
    Reviews
    Nature Reviews Neurology
    Volume: 10, P: 372-385

  • This Review presents an overview of vaccine-based immunotherapies for human glioma. Although efficacy remains unproven for the vaccines in clinical development, Weller and colleagues highlight promising strategies for antagonizing glioma-associated immunosuppression and boosting immune responses in vaccinated patients. Ultimately, such approaches might help to control the growth of human gliomas.

    • Michael Weller
    • Patrick Roth
    • John H. Sampson
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 363-374

  • The DNA repair enzymeO6-methylguanine-DNA methyltransferase (MGMT) antagonizes the effects of alkylating agents, and its expression is associated with resistance to cancer therapy based on these compounds. Weller et al. consider the prognostic and predictive value of MGMT gene silencing in gliomas and describe the assays that are commonly used to evaluate MGMT status, focusing particularly on MGMT promoter methylation, which is the key mechanism of MGMTgene silencing.

    • Michael Weller
    • Roger Stupp
    • Monika E. Hegi
    Reviews
    Nature Reviews Neurology
    Volume: 6, P: 39-51